Under construction – not a live service
Sign in
Not yet taking people in ChinaPhase 3

Long-term safety of admilparant in people with pulmonary fibrosis

Checks long-term safety of admilparant in people who finished earlier pulmonary fibrosis studies.

Plain-language title generated from the registry record
Registry title: Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

Key facts

Where
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Hohhot, Lanzhou, Nanjing, Ningbo, Shandong, Shanghai, Shanghai Shi, Shenyang, Shenzhen, Shenzhen Shi, Shijiazhuang, Suzhou, Tianjin, Wuhan, Wuxi, Xi'an, Xuzhou, Yichang Shi, Yinchuan, and Zhengzhou, ChinaSee the 40 sites
Phase
Phase 3

Where in China

  • BeijingBeijing, ChinaNo longer taking part
  • BeijingBeijing, ChinaNo longer taking part
  • BeijingBeijing, ChinaNo longer taking part
  • ChangshaChangsha, ChinaNo longer taking part
  • ChengduChengdu, ChinaNo longer taking part
  • ChengduChengdu, ChinaNo longer taking part
  • GuangzhouGuangzhou, ChinaNo longer taking part
  • GuangzhouGuangzhou, ChinaNo longer taking part
  • HangzhouHangzhou, ChinaNo longer taking part
  • HangzhouHangzhou, ChinaNo longer taking part
  • HangzhouHangzhou, ChinaNo longer taking part
  • HefeiHefei, ChinaNo longer taking part
  • HefeiHefei, ChinaNo longer taking part
  • HohhotHohhot, ChinaNo longer taking part
  • LanzhouLanzhou, ChinaNo longer taking part
  • NanjingNanjing, ChinaNo longer taking part
  • NingboNingbo, ChinaNo longer taking part
  • ShandongShandong, ChinaNo longer taking part
  • ShanghaiShanghai, ChinaNo longer taking part
  • ShanghaiShanghai, ChinaNo longer taking part
  • ShanghaiShanghai, ChinaNo longer taking part
  • ShanghaiShanghai, ChinaNo longer taking part
  • ShanghaiShanghai, ChinaNo longer taking part
  • Shanghai ShiShanghai Shi, ChinaNo longer taking part
  • ShenyangShenyang, ChinaNo longer taking part
  • ShenyangShenyang, ChinaNo longer taking part
  • ShenzhenShenzhen, ChinaNo longer taking part
  • Shenzhen ShiShenzhen Shi, ChinaNo longer taking part
  • ShijiazhuangShijiazhuang, ChinaNo longer taking part
  • SuzhouSuzhou, ChinaNo longer taking part
  • TianjinTianjin, ChinaNo longer taking part
  • TianjinTianjin, ChinaNo longer taking part
  • WuhanWuhan, ChinaNo longer taking part
  • WuxiWuxi, ChinaNo longer taking part
  • Xi'anXi'an, ChinaNo longer taking part
  • XuzhouXuzhou, ChinaNo longer taking part
  • Yichang ShiYichang Shi, ChinaNo longer taking part
  • YinchuanYinchuan, ChinaNo longer taking part
  • ZhengzhouZhengzhou, ChinaNo longer taking part
  • ZhengzhouZhengzhou, ChinaNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Bristol-Myers Squibb
Trial code
NCT07441408EU 2025-522373-10-00
Record updated
30 October 2026
Original description
The purpose of this study is to evaluate the long-term safety and tolerability of Admilparant in participants who completed participation in parent studies IM027-068 (for idiopathic pulmonary fibrosis (IPF)) and IM027-1015 (for progressive pulmonary fibrosis (PPF)).Read full original descriptionShow less

An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

The purpose of this study is to evaluate the long-term safety and tolerability of Admilparant in participants who completed participation in parent studies IM027-068 (for idiopathic pulmonary fibrosis (IPF)) and IM027-1015 (for progressive pulmonary fibrosis (PPF)).

Inclusion: Participants must have participated in either IM027068 or IM0271015 without discontinuing treatment permanently due to withdrawal of informed consent in either IM027068 or IM0271015.

Exclusion: Any disease/condition that, in the investigator's judgment, may pose an unacceptable safety risk for study participation; Exhibit symptoms of heart failure at rest; History of lung reduction surgery or lung transplant; Participants with known PAH (Pulmonary Arterial Hypertension) who has been on single-drug therapy that now requires multi-drug therapy; Any AE that resulted in permanent discontinuation of IMP in IM027068 or IM0271015; Other protocol-defined Inclusion/Exclusion criteria apply.

ClinicalTrials.gov NCT07441408 · EU CTIS 2025-522373-10-00

Under construction, not live – Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis (NCT07441408) – Frontlight Research